Table 3. Univariate and multivariate Cox regression analyses to identify prognostic factors for EFS.
| Factor | Univariate analysis | Multivariate analysis | |||
| HR (95% CI) | P | HR (95% CI) | P | ||
| EFS, event-free survival; HR, hormone receptor; HER2, human epidermal growth factor receptor 2; HR, hazard ratio; 95% CI, 95% confidence interval. | |||||
| T3/T4 vs. T0/T1/T2 | 1.060 (0.458−2.453) | 0.892 | 1.116 (0.465−2.681) | 0.805 | |
| Stage: III vs. II | 4.349 (0.585−31.312) | 0.151 | 5.167 (0.673−39.653) | 0.114 | |
| HR+ vs. HR− | 0.619 (0.268−1.432) | 0.263 | 0.593 (0.246−1.431) | 0.245 | |
| HER2 2+/FISH+ vs. HER2 3+ | 1.342 (0.457−3.947) | 0.593 | 0.730 (0.236−2.260) | 0.585 | |
| Monotherapy vs. dual-therapy | 1.062 (0.463−2.437) | 0.886 | 1.533 (0.648−3.630) | 0.331 | |
| Insensitivity vs. sensitivity | 6.957 (2.580−18.756) | <0.001 | 8.637 (3.091−24.136) | <0.001 | |